Novo Nordisk
Note: This is a daily stock update and the information stands true as of 29/08/24, 09:00 CEST.
Company Update:
Research suggests that patients on certain types of diabetes drugs, especially SGLT-2 class of medicines, are less likely to develop dementia. Even Novo’s diabetes/weight-loss drug molecule semaglutide is being tested for Alzheimer’s in late-stage trials. In case Novo’s drug and others like it succeed in treating Alzheimer’s, it should be good news for the involved pharmas as well as the patients, as:
Expert Opinion:
The list of potential benefits of Semaglutide seems to be infinite. If confirmed, this will further boost demand for Novo’s (and Eli Lily’s products). At this stage the main problem of Novo is to meet demand with increased production. Yes at some points other actors (notably Roche) will join the party but so far the prospects of Novo and Eli Lily remain very strong. The recent pullback in Novo's share price doesn’t modify our positive stance in the name. Still a stock to have in portfolio for at least the next couple of years.
For daily updates, subscribe to our newsletter and for detailed daily updates, reach our to us at sales@alphavalue.eu
Company Update:
Research suggests that patients on certain types of diabetes drugs, especially SGLT-2 class of medicines, are less likely to develop dementia. Even Novo’s diabetes/weight-loss drug molecule semaglutide is being tested for Alzheimer’s in late-stage trials. In case Novo’s drug and others like it succeed in treating Alzheimer’s, it should be good news for the involved pharmas as well as the patients, as:
- The cost of these diabetes/obesity drugs is much less than the currently approved Alzheimer’s drugs from Eisai/Biogen and Eli Lilly
- The latest diabetes/obesity drugs have a well-proven safety record.
Expert Opinion:
The list of potential benefits of Semaglutide seems to be infinite. If confirmed, this will further boost demand for Novo’s (and Eli Lily’s products). At this stage the main problem of Novo is to meet demand with increased production. Yes at some points other actors (notably Roche) will join the party but so far the prospects of Novo and Eli Lily remain very strong. The recent pullback in Novo's share price doesn’t modify our positive stance in the name. Still a stock to have in portfolio for at least the next couple of years.
For daily updates, subscribe to our newsletter and for detailed daily updates, reach our to us at sales@alphavalue.eu
Subscribe to our blog
Alphavalue Morning Market Tip
Solid start of 2025 with signs of recovery in key markets.